A carregar...

IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity

Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and others have shown that oncogenic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bassères, Daniela S., Ebbs, Aaron, Cogswell, Patricia C., Baldwin, Albert S.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063255/
https://ncbi.nlm.nih.gov/pubmed/24955217
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!